Research programme: erectile dysfunction therapies - Sagene Pharmaceuticals

Drug Profile

Research programme: erectile dysfunction therapies - Sagene Pharmaceuticals

Alternative Names: Selegiline/phosphodiesterase-5 inhibitor; SPI-1972

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sagene Pharmaceuticals
  • Class
  • Mechanism of Action Monoamine oxidase B inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Erectile dysfunction

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in USA (PO)
  • 12 Sep 2011 Preclinical trials in Erectile dysfunction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top